Pulmonary Arterial Hypertension Market to Grow at a CAGR of 3.6% in the 7MM During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - Insmed (treprostinil palmitil inhalation powder (TPIP)), Respira Therapeutics (RT234), Gossamer Bio

As per DelveInsight, the Pulmonary Arterial Hypertension Market is anticipated to grow in the coming years owing to the increasing patient population in the 7MM, extensive research and development activities of pharmaceutical companies, and the expected launch of approved therapies in the market.

While the current FDA-approved drugs improve the quality of life and hemodynamic parameters, none offer a cure for PAH. Extensive research efforts have led to the emergence of innovative therapeutic approaches in the area of PAH. The Pulmonary Arterial Hypertension therapeutics market has a promising outlook with many emerging therapies such as CS1, Ralinepag, RVT-1201, Sotatercept, Bardoxolone methyl, inhaled dry powder treprostinil, PB1046 Injection, CXA-10, and several others.

DelveInsight's "Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pulmonary Arterial Hypertension Market Size and Share in the 7MM (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Pulmonary Arterial Hypertension market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Pulmonary Arterial Hypertension: An Overview
PAH is a rare, progressive disorder characterized by hypertension in the pulmonary arteries for no apparent reason. It was defined by the 6th World Symposium on Pulmonary Hypertension (WSPH) as a resting mean pulmonary artery pressure (mPAP) of 20 mm Hg or greater, a normal end-expiratory pulmonary artery wedge pressure (PAWP) less than or equal to 15 mm Hg, and a PVR of greater than or equal to 3 Wood units.

PAH is further classified by the WHO into the following types: idiopathic PAH (IPAH), heritable PAH (HPAH), drug and toxin-induced PAH, and PAH associated with other diseases and disorders. The associated conditions include cirrhosis, HIV, congenital heart disease, and connective tissue diseases like scleroderma, among others.

Pulmonary Arterial Hypertension Market Key Facts
- The Pulmonary Arterial Hypertension Market size in the seven major markets was approximately USD 4,871.0 million in 2021, which is further expected to increase by 2032.
- Among the 7MM countries, the US accounted for the highest market size of Pulmonary Arterial Hypertension with approximately USD 3,848.1 million in 2021, which is likely to increase by 2032.
- Among EU4 and the United Kingdom, Germany accounted for approximately USD 211.2 million in 2021, followed by France with approximately USD 169.1 million in the respective year, while Spain accounted for the lowest market with approximately USD 117.0 million in 2021.
- Japan accounted for approximately USD 243.0 million in 2021, which is expected to increase by 2032.
- The total prevalent cases of PAH in the 7MM were estimated to be approximately 87,000+ cases in 2021.
- Among the 7MM, the United States accounted for nearly 58% of the total diagnosed prevalent cases of Pulmonary Arterial Hypertension in the 7MM in the year 2021, which is expected to increase further by 2032.
- As per DelveInsight analysis, in EU4 and the United Kingdom, Germany had the highest total diagnosed prevalent cases of Pulmonary Arterial Hypertension, with approximately 5,065 in 2021, while Spain had the lowest diagnosed prevalent population of Pulmonary Arterial Hypertension, with approximately 2,826 cases in 2021.
- An increase in the growth of the market is expected due to upcoming Pulmonary Arterial Hypertension (PAH) therapies such as CS1 (Cereno Scientific), Ralinepag (Arena Pharmaceuticals), RVT-1201 (Altavant Sciences), Sotatercept (Acceleron Pharma, Inc.), Bardoxolone methyl (Reata Pharmaceuticals, Inc.), Inhaled dry powder treprostinil (Liquidia Technologies, Inc.), PB1046 Injection (PhaseBio Pharmaceuticals Inc.), and CXA-10 (Complexa, Inc.).

Pulmonary Arterial Hypertension Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Pulmonary Arterial Hypertension market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Pulmonary Arterial Hypertension market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Pulmonary Arterial Hypertension Market will Grow by 2032:
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pulmonary Arterial Hypertension Epidemiology
The epidemiology section covers detailed insights into the historical and current Pulmonary Arterial Hypertension patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Pulmonary Arterial Hypertension Epidemiology Segmented by -
- Total Prevalent Patient Population of PAH in the 7MM (2019-2032)
- Subtype Specific Prevalence of PAH in the 7MM (2019-2032)
- Gender-specific Prevalence of PAH in the 7MM (2019-2032)

Get Key Insights Into the Evolving Pulmonary Arterial Hypertension Epidemiology Trends:
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to be launched during the study period. The analysis covers Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pulmonary Arterial Hypertension Therapeutics Assessment
There are several major pharma and biotech which are developing therapies for Pulmonary Arterial Hypertension. Currently, Liquidia Technologies is leading the therapeutics market with its Pulmonary Arterial Hypertension drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Pulmonary Arterial Hypertension Therapeutics Market Include:
- Merck
- United Therapeutics
- Liquida Technologies
- Tenax Therapeutics
- Respira Therapeutics
- Gossamer Bio
- Pharmosa Biopharma
- Aerovate Therapeutics
- Insmed
- Novartis
- Cumberland Pharmaceuticals
- Enzyvant Therapeutics
- AstraZeneca
- Cereno Scientific
- PhaseBio Pharmaceutical
And Many Others

Pulmonary Arterial Hypertension Drugs Covered in the Report Include:
- Sotatercept (MK-7962): Merck
- Ralinepag: United Therapeutics)
- RT234 (vardenafil inhalation powder): Respira Therapeutics
- seralutinib (GB002): Gossamer Bio
- YUTREPIA (inhaled dry powder formulation of treprostinil): Liquidia Technologies)
- TNX-201 (Tenax Therapeutics)
And Many More

Learn More About the Emerging Therapies & Key Companies in the Pulmonary Arterial Hypertension Therapeutics Market:
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pulmonary Arterial Hypertension Competitive Intelligence Analysis
4. Pulmonary Arterial Hypertension Market Overview at a Glance
5. Pulmonary Arterial Hypertension Background and Overview
6. Pulmonary Arterial Hypertension Patient Journey
7. Pulmonary Arterial Hypertension Epidemiology and Patient Population
8. Pulmonary Arterial Hypertension Treatment Algorithm, Current Treatment, and Medical Practices
9. Pulmonary Arterial Hypertension Unmet Needs
10. Key Endpoints of Pulmonary Arterial Hypertension Treatment
11. Pulmonary Arterial Hypertension Marketed Products
12. Pulmonary Arterial Hypertension Emerging Therapies
13. Pulmonary Arterial Hypertension Seven Major Market Analysis
14. Attribute Analysis
15. Pulmonary Arterial Hypertension Market Outlook (7 major markets)
16. Pulmonary Arterial Hypertension Access and Reimbursement Overview
17. KOL Views on the Pulmonary Arterial Hypertension Market.
18. Pulmonary Arterial Hypertension Market Drivers
19. Pulmonary Arterial Hypertension Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Trending Market Research Reports 2032 | DelveInsight

Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services

Vital Sign Monitors Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market

Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market

Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market

B-Cell Maturation Antigen Targeted Therapies Market- https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market

UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

Oncolytic Virus Cancer Therapy Pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Shingles Market- https://www.delveinsight.com/report-store/shingles-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

This release was published on openPR.